早産とPROM検査の市場：検査タイプ、エンドユーザー、地域別、2026～2032年

早産とPROM検査市場の評価-2026～2032年

早産とPROM（膜早期破裂）検査市場は、早産と膜破裂の診断と治療に焦点を当てています。早産率の上昇と診断技術の進歩が成長の原動力となっています。新興市場は、ヘルスケアの重要性に対する人々の意識が高まるにつれて成長しています。このため、市場規模は2024年に23億9,000万米ドルを突破し、2032年には約41億1,000万米ドルの評価額に達する可能性が高いです。

この市場の市場は、早期発見・早期管理のための新規検査を開発しています。非侵襲的手技とポイントオブケア診断が未来を定義しています。ヘルスケア専門家が患者の転帰を改善し、早産の問題を予防しようと努力する中、正確で迅速な所見に対する需要が市場成長を牽引しています。早産とPROM検査に対する需要の高まりが、2026～2032年のCAGR 7.76%での市場成長を可能にしています。

早産とPROM検査市場定義/概要

早産は、妊娠37週以前に起こる分娩と定義され、赤ちゃんの健康上の合併症を引き起こす可能性があります。PROM検査陣痛が始まる前に羊膜嚢が破れる膜早期破裂（PROM）を評価することで、リスクを評価し、母親と赤ちゃんの両方の困難を回避するための管理を導きます。

早産とPROM検査は、ハイリスク妊娠の発見に役立ちます。早産検査は早期分娩の可能性を判定し、PROM検査は膜破裂を検出することで、感染症の予防や早産リスクの管理に役立ちます。両者とも早期介入と乳児の転帰改善に不可欠です。

早産とPROM検査の将来的な応用には、早期発見の増加、標的治療の指導、治療アプローチの個別化などが含まれます。早産率とそれに関連する困難を最小化するために、予測バイオマーカーを組み合わせ、非侵襲的診断法を確立し、臨床ガイドラインを改訂することによって進歩がもたらされるであると考えられます。

早産の有病率の増加は早産とPROM検査市場の成長を促進するか？

早産の増加により、早産とPROM検査産業は成長すると考えられます。2021年、米国の早産率は2020年の10.1%から10.5%に増加し、ほぼ10人に1人が早産児となります。2014～2021年にかけて、早産率は12％上昇し、世界中で毎年およそ1,500万人の赤ちゃんが早産で生まれています。

PROMは米国では妊娠の2～3％を合併し、早産の30～40％に関係していることから、適切な診断ソリューションの重要性が強調されています。このような罹患率の増加は、新たな診断ツールと介入の必要性を浮き彫りにしており、ヘルスケア従事者が早産とそれに関連する結果の発生を効果的に管理・減少させようと努力する中で、市場拡大の原動力となっています。

検査費用の高さは早産とPROM検査市場の妨げになるか？

検査コストの高さは、早産とPROM検査市場をある程度制限する可能性があります。先進技術やヘルスケア施設の影響を受ける検査費用は、特に低資源国ではかなりの障壁となりえます。

例えば米国では、早産への対応に多大なコストがかかり、1件あたり6万5,000米ドル、年間262億米ドルもの負担がヘルスケアシステムにのしかかります。このような高額な出費は、一部のヘルスケア関係者や患者が先進的検査を受けることを躊躇させる可能性があります。しかし、市場では、より経済的で費用対効果の高い検査法や技術革新への需要が高まる可能性があります。コストを下げ、アクセシビリティを向上させる努力は、産業全体の成長を支えるとともに、こうした問題を相殺するのに役立つと考えられます。

目次

第1章 世界の早産・妊娠検査市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の早産とPROM検査市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 早産とPROM検査の世界市場：タイプ別

• 概要
• 早産検査
  • 骨盤検査
  • 超音波検査
  • 子宮モニタリング
  • バイオマーカー
• PROM検査
  • ニトラジンテスト
  • ファーニング検査
  • プーリング
  • 超音波検査
  • 胎児フィブロネクチン検査
  • バイオマーカー検査

第6章 早産とPROM検査の世界市場：エンドユーザー別

• 概要
• 病院
• 診断ラボ
• その他

第7章 早産とPROM検査の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の早産とPROM検査市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Qiagen Sciences, LLC
• Hologic, Inc.
• CooperSurgical, Inc
• Abbott Laboratories
• Medix Biochemica
• Sera prognostics
• Clinical Innovations, LLC
• Biosynex
• NX Prenatal, Inc.
• IQ Products

第10章 付録

• 関連調査

Preterm Birth and PROM Testing Market Valuation - 2026-2032

The preterm birth and PROM (Premature Rupture of Membranes) testing market focuses on the diagnosis and treatment of early births and membrane rupture. The growth is being driven by rising preterm birth rates and advances in diagnostic technologies. Emerging markets are growing as people become more aware of the importance of healthcare. This is likely to enable the market size to surpass USD 2.39 Billion in 2024 to reach a valuation of around USD 4.11 Billion by 2032.

Leading manufacturers in this market are developing novel tests for early detection and management. Non-invasive procedures and point-of-care diagnostics are defining the future. Demand for precise, quick findings drives market growth as healthcare professionals strive to improve patient outcomes and prevent preterm birth problems. The rising demand for Preterm Birth and Prom Testing is enabling the market grow at a CAGR of 7.76% from 2026 to 2032.

Preterm Birth and PROM Testing Market: Definition/ Overview

Preterm birth is defined as a delivery occurring before 37 weeks of pregnancy, which may result in health complications for the baby. PROM Testing Evaluation for Premature Rupture of Membranes (PROM), in which the amniotic sac ruptures before labor begins, assesses risks and guides management to avoid difficulties for both mother and baby.

Preterm birth and PROM (preterm rupture of membranes) testing aid in detecting high-risk pregnancies. Preterm birth testing determines the possibility of early labor, whereas PROM testing detects membrane rupture, which helps to prevent infections and manage preterm delivery risks. Both are critical for early intervention and better infant outcomes.

Future applications of preterm birth and PROM (Premature Rupture of Membranes) testing include increasing early detection, guiding targeted therapies and personalizing treatment approaches. To minimize preterm birth rates and related difficulties, advances will be made by combining predictive biomarkers, establishing non-invasive diagnostic procedures and revising clinical guidelines.

Will Increasing Prevalence of Preterm Births Boost the Preterm Birth and PROM Testing Market Growth?

The rising occurrence of premature births will drive the preterm birth and PROM testing industry. In 2021, the U.S. preterm birth rate increasing to 10.5%, up from 10.1% in 2020, with almost one in every ten babies born preterm. Between 2014 and 2021, the rate climbed by 12%, with roughly 15 million babies born preterm around the world each year.

PROM complicates 2-3% of pregnancies in the United States and is connected with 30-40% of premature births, emphasizing the importance of appropriate diagnostic solutions. This rising incidence highlights the need for new diagnostic tools and interventions, which are driving market expansion as healthcare practitioners strive to effectively manage and reduce the occurrence of preterm births and related consequences.

Will High Cost of Testing Hamper the Preterm Birth and PROM Testing Market?

The high cost of testing may limit the preterm birth and PROM testing market to some extent. Testing costs, which are influenced by advanced technologies and healthcare facilities, can be a considerable barrier, especially in low-resource nations.

In the United States, for example, handling premature births incurs significant costs, with each case costing $65,000 and adding to a $26.2 billion yearly burden on the healthcare system. This hefty expense may dissuade some healthcare practitioners and patients from seeking advanced testing. However, it may increase demand for more economical, cost-effective testing methods and innovations in the marketplace. Efforts to lower costs and enhance accessibility could help to offset these issues while also supporting overall industry growth.

Category-Wise Acumens

Will Increasing Effectiveness in Monitoring Fetal and Uterine Health Drive the Test Type Segment?

Increasing efficacy in monitoring fetal and uterine health will drive the test type sector. Advances in technologies such as ultrasound and biomarker tests improve diagnostic accuracy, enabling for more effective care of preterm deliveries and PROM complications. Enhanced ultrasound capabilities offer more detailed images and insights into fetal development and uterine problems, resulting in better early identification and intervention techniques.

Similarly, advances in biomarker testing enable more exact identification of risk factors and illnesses. As these technologies improve in effectiveness, they are likely to gain traction and drive market expansion. The capacity to better monitor and manage pregnancy issues will result in increasing demand for advanced testing solutions, propelling the test type sector forward.

Will Increasing Wide Range of Diagnostic Tests and Immediate Clinical Interventions Drive the End-User Segment?

The growing number of diagnostic tests and the capacity to deliver quick clinical treatments will propel the end-user segment. Hospitals are well-positioned to profit from advances in diagnostic technologies because of their comprehensive care infrastructure, which includes access to a variety of diagnostic tests and specialists.

Hospitals are the recommended site for these services because they can perform a wide range of diagnostics, such as ultrasounds and biomarker assessments, as well as respond rapidly to preterm birth and PROM complications. As diagnostic capabilities improve and clinical interventions become more advanced, hospitals will continue to increase their use of preterm birth and PROM testing. This trend will continue to boost the end-user segment, cementing hospitals' dominance in this market.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in North America?

Advanced healthcare infrastructure will fuel the market in North America, enabling the region hold major share. According to the US Department of Health and Human Services, by 2020, 96% of non-federal acute care hospitals will have implemented certified electronic health records (EHRs). Additionally, 76% of U.S. hospitals used telemedicine technologies, such as video consultations, to improve patient care and access to services.

This solid infrastructure enables the effective deployment and maintenance of modern diagnostic tests for preterm delivery and PROM. The combination of EHRs and telemedicine enhances data management, diagnostic accuracy and allows for rapid treatments. These technological developments not only improve clinical capabilities, but also promote adoption of testing solutions, resulting in market growth in North America.

Will Increasing Healthcare Investments Drive the Market in Asia Pacific Region?

The Asia Pacific region is expected to exhibit rapid growth in the preterm birth and premature rupture of membranes (PROM) testing market due to increase in healthcare investments. This growth is primarily owing to improvement in healthcare infrastructure which results in better-equipped hospitals and clinics with advanced medical technologies, enhancing the capacity for more sophisticated prenatal care and diagnostic services. Thus, access to advanced diagnostic tools improves the accuracy and timeliness of diagnoses, leading to better outcomes for mothers and infants.

Aso, providing better training and education for healthcare professionals results in improved prenatal care and reduced incidence of preterm births and PROM. In response to the need for improvement in prenatal care, there is high demand for research and development activities in diagnostic tests and treatments, such as new biomarkers or non-invasive tests.

Public health campaigns can raise awareness about the risks of preterm birth and the importance of prenatal care, leading to earlier detection and prevention strategies. Expanding healthcare coverage can make prenatal testing more accessible and affordable for a larger population, increasing the usage of PROM and preterm birth testing services.

The implementation of maternal health programs is projected to facilitate the integration of preterm birth and PROM testing into broader maternal and child health programs, leading to better preventive care and management strategies.

Furthermore, increasing healthcare investments in the Asia Pacific region are expected to significantly boost the market for preterm birth and PROM testing, improving healthcare outcomes for mothers and babies while reducing long-term healthcare costs.

Competitive Landscape

The preterm birth and PROM testing market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the preterm birth and prom testing market include:

Qiagen N.V.

Hologic, Inc.

Cooper Surgical, Inc.

Abbott

Medixbiochemica

Sera Prognostics

Clinical Innovations, LLC

Biosynex

NX Prenatal, Inc.

1Q Products

Latest Developments

In May 2022, Sera Prognostics and the Newborn Foundation launched the Every Mother, Every Baby project. The purpose is to educate physicians, policymakers and public health stakeholders on the importance of validated biomarker-based preterm risk assessment tests, such as Sera's PreTRM test, in improving neonatal health outcomes maternal health outcomes.

In November 2021, Sera Prognostics has partnered with PreemieWorld, GLO Preemies and the Alliance for Black NICU Families to empower and support families affected by preterm birth.

Preterm Birth and Prom Testing Market, By Category

• Test Type:
• Preterm Birth Tests
• Pelvic Exam
• Ultrasound
• Uterine Monitoring
• Biomarker
• PROM Tests
• Nitrazine Test
• Ferning Test
• Pooling
• Ultrasound
• Fetal Fibronectin Test
• Biomarker Test
• End-User:
• Hospitals
• Diagnostics Laboratories
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRETERM BIRTH AND PROM TESTING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY TYPE

• 5.1 Overview
• 5.2 Preterm Birth Tests
  • 5.2.1 Pelvic Exam
  • 5.2.2 Ultrasound
  • 5.2.3 Uterine Monitoring
  • 5.2.4 Biomarker
• 5.3 PROM Tests
  • 5.3.1 Nitrazine Test
  • 5.3.2 Ferning Test
  • 5.3.3 Pooling
  • 5.3.4 Ultrasound
  • 5.3.5 Fetal Fibronectin Test
  • 5.3.6 Biomarker Test

6 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY END USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Diagnostic Laboratories
• 6.4 Others

7 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Qiagen Sciences, LLC
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Hologic, Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 CooperSurgical, Inc
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Abbott Laboratories
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Medix Biochemica
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Sera prognostics
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Development
• 9.7 Clinical Innovations, LLC
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Biosynex
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 NX Prenatal, Inc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Development
• 9.10 IQ Products
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Development

10 Appendix

• 10.1 Related Research